Sanofi Set To Seek $442 Million From Apotex For Plavix Infringement
This article was originally published in The Pink Sheet Daily
Executive Summary
District court denies Apotex's request to stay the award of damages; Patent Office reexamination finds Plavix patent is valid.
You may also be interested in...
Sanofi, EU Medicines Agencies Flag Acquired Hemophilia Link To Clopidogrel
Although only 12 cases have been reported to the company, extensive use of the anti-platelet drug and shortfalls in adverse event reporting systems mean the number could rise.
Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix
A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.
Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix
A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.